The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients

AIDS

Volumn 27, Issue 17, 2013, Pages 2707-2714

  Mandorfer, Mattias ^a   Neukam, Karin ^b   Reiberger, Thomas ^a   Payer, Berit A ^a   Rivero, Antonio ^c   Puoti, Massimo ^d   Boesecke, Christoph ^e   Baumgarten, Axel ^f   Grzeszczuk, Anna ^g   Zangerle, Robert ^h   Meyer Olson, Dirk ⁱ   Rockstroh, Jürgen K ^e   Trauner, Michael ^a   Pineda, Juan A ^b   Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e UNIVERSITY OF BONN   (Germany)

^f Praxis Driesener Strasze   (Germany)

^g MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

HIV HCV coinfection; Interleukin 28B rs12979860 single nucleotide polymorphism; Liver fibrosis; Pegylated interferon; Response guided therapy; Ribavirin

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERONS; INTERLEUKINS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RETROSPECTIVE STUDIES; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84888296566     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000432460.44593.ef     Document Type: Article

References (32)

1. Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24:1537-1548.
2. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44:S6-S9.
3. Reiberger T, Ferlitsch A, Sieghart W, Kreil A, Breitenecker F, Rieger A, et al. HIV-HCV co-infected patients with low CD4R cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepatitis 2010; 17:400-409.
4. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 2001; 33:562-569.
5. Wandeler G, Gsponer T, Bregenzer A, Gunthard HF, Clerc O, Calmy A, et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: A rapidly evolving epidemic. Clin Infect Dis 2012; 55:1408-1416.
6. Vogel M, Page E, Boesecke C, Reiberger T, Schwarze-Zander C, Mauss S, et al. Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals. Clin Infect Dis 2012; 54:556-559.
7. Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50:407-413.
8. Berenguer J, Rodriguez E, Miralles P, Von Wichmann MA, Lopez-Aldeguer J, Mallolas J, et al. Sustained virological response to interferon plus ribavirin reduces nonliver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis 2012; 55:728-736.
9. Rockstroh J, Bhagani S, Bruno R, Garća D, Journiac M, Lacombe K, et al. European AIDS Clinical Society (EACS) Guidelines. Version 6.1. Paris, France: EACS; 2012.
10. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-458.
11. Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology 2010; 138:503-512.
12. Ferenci P. Optimal treatment duration for patients with HCV genotype 1 infection. J Viral Hepat 2012; 19 Suppl 1:7-13.
13. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007; 46: 1688-1694.
14. Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131:451-460.
15. Van den Eynde E, Crespo M, Esteban JI, Jardi R, Ribera E, Carbonell J, et al. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: A pilot trial. Clin Infect Dis 2009; 48:1152-1159.
16. Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007; 23:972-982.
17. Stattermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9:344-350.
18. Maieron A, Metz-Gercek S, Hackl F, Ziachehabi A, Fuchsteiner H, Luger C, et al. Antiviral treatment of chronic hepatitis C in clinical routine. Wien Klin Wochenschr 2010; 122:237-242.
19. Medrano J, Neukam K, Rallon N, Rivero A, Resino S, Naggie S, et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2010; 51:1209-1216.
20. Payer BA, Reiberger T, Aberle J, Ferenci P, Holzmann H, Rieger A, et al. IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. Eur J Clin Invest 2012; 42:599-606.
21. Neukam K, Camacho A, Caruz A, Rallon N, Torres-Cornejo A, Rockstroh JK, et al. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. J Hepatol 2012; 56:788-794.
22. Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010; 51:788-795.
23. Vergara S, Macias J, Rivero A, Gutierrez-Valencia A, Gonzalez-Serrano M, Merino D, et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007; 45:969-974.
24. Reiberger T, Ferlitsch A, Payer BA, Pinter M, Schwabl P, Stift J, et al. Noninvasive screening for liver fibrosis and portal hypertension by transient elastography: A large single center experience. Wien Klin Wochenschr 2012; 124:395-402.
25. Theise ND. Liver biopsy assessment in chronic viral hepatitis: A personal, practical approach. Modern Pathol 2007; 20 Suppl 1:S3-S14.
26. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-350.
27. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferonalfa-2a plus ribavirin. Gastroenterology 2006; 130:1086-1097.
28. Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology 2010; 52:1201-1207.
29. Sanchez-Conde M, Montes-Ramirez ML, Miralles P, Alvarez JM, Bellon JM, Ramirez M, et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat 2010; 17:280-286.
30. Loko MA, Castera L, Dabis F, Le Bail B, Winnock M, Coureau G, et al. Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort. Am J Gastroenterol 2008; 103: 1973-1980.
31. Mandorfer M, Reiberger T, Payer BA, Ferlitsch A, Breitenecker F, Aichelburg MC, et al. Low vitamin D levels are associated with impaired virologic response to PEGIFN R RBV therapy in HIVhepatitis C virus coinfected patients. AIDS 2013; 27:227-232.
32. Mandorfer M, Reiberger T, Payer BA, Breitenecker F, Aichelburg MC, Obermayer-Pietsch B, et al. Revisiting predictors of virologic response to PEGIFN R RBV therapy in HIV-/HCVcoinfected patients: the role of metabolic factors and elevated GGT levels. J Viral Hepatitis 2013.